Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1509-1515

  Plummer, Mark P ^a,b,c   Jones, Karen L ^c,d   Annink, Chris E ^b   Cousins, Caroline E ^b   Meier, Juris J ^e   Chapman, Marianne J ^a,b,c   Horowitz, Michael ^c,d   Deane, Adam M ^a,b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c Centre of Clinical Research Excellence in Nutritional Physiology   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLGLUCOSE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; SULFUR; TECHNETIUM 99M; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INCRETIN;

ADULT; AGED; ARTICLE; BEEF; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOOD INTAKE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; ISOTOPE LABELING; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; STOMACH SCINTISCANNING; VOLUNTEER; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHYSIOLOGY;

AGED; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED;

EID: 84901390701     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1813     Document Type: Article

References (39)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596
2. Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013;15: 3-14
3. Schirra J, Leicht P, Hildebrand P, et al. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 1998; 156:177-186
4. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36:741-744
5. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-1246
6. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-2725
7. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62: 173-181
8. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetesdrelationship to postprandial glycemia. Regul Pept 2013;185:1-8
9. Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose. Gastroenterology 1983;85:76-82
10. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013; 30:81-101
11. Schvarcz E, Palḿer M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care 1995;18:674-676
12. Russo A, Stevens JE, Chen R, et al. Insulininduced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005;90: 4489-4495
13. MacGregor IL, Gueller R, Watts HD, Meyer JH. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976;70: 190-196
14. Schvarcz E, Palḿer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997;113:60-66
15. Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999;22:339-344
16. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
17. Schirra J, Houck P, Wank U, Arnold R, Goke B, KatschinskiM. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000;46:622-631 (Pubitemid 30305778
18. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273: E981-E988
19. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
20. NauckM. Therapeutic potential of glucagonlike peptide 1 in type 2 diabetes. Diabet Med 1996;13(Suppl. 5):S39-S43
21. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215-221
22. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010;38:1261-1269
23. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006;91:1916-1923
24. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1dCorrelation within subjects. BMJ 1995; 310:446
25. Schvarcz E, Palḿer M, Aman J, Berne C. Atropine inhibits the increase in gastric emptying during hypoglycemia in humans. Diabetes Care 1995;18:1463-1467
26. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002;282:G424-G431 (Pubitemid 34651657
27. Schirra J, NicolausM,Woerle HJ, Struckmeier C, Katschinski M, Goke B: GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21: 609-618
28. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA. Vagallymediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 2009;587:4749-4759
29. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-121
30. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.diabetes 2004;53:2397-2403
31. Pieber T, Deller S, Brunner M, et al. Effects of liraglutide as adjunct to insulin on counterregulatory hormone response to hypoglycemia in type 1 diabetes: a randomized, double-blind, crossover trial. Abstract presented at the 73rd Scientific Sessions of the American Diabetes Association, 21-25 June 2013, at the McCormick Place Convention Center, Chicago, Illinois
32. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994;78: 1341-1348
33. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998;43:2284-2290 (Pubitemid 28487260
34. Sandoval D, Dunki-Jacobs A, Sorrell J, Seeley RJ, D'Alessio DD. Impact of intestinal electrical stimulation on nutrient-induced GLP-1 secretion in vivo. Neurogastroenterol Motil 2013; 25:700-705
35. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 Get-Goal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-1231
36. Gonlachanvit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003;48:488-497
37. Samsom M, Vermeijden JR, Smout AJ, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003;26: 3116-3122
38. Korzon-Burakowska A, Hopkins D, Matyka K, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes.diabetes Care 1998;21:283-290
39. Berlie H, Hurren KM, Pinelli NR. Glucagonlike peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes 2012;5:165-174